



Ke Geng

Partner

Beijing

D: +86-10-6563-4261

kgeng@omm.com

Ke Geng, managing partner of the Beijing office, advises Chinese companies in connection with outbound investments and exchange listings in the United States or Hong Kong, as well as the privatization of US or HK listed companies, private equity and venture capital financing, mergers and acquisitions transactions, and general corporate matters. Ke provides client-oriented, proactive, and cost-effective services to companies spanning a wide variety of industries, including healthcare, technology, media, and telecommunications (TMT).

Prior to joining O'Melveny, Ke practiced at another large international law firm.

Experience

Offshore Public Offerings

- Honliv Healthcare Management Group Company Limited in its US\$41.3 million IPO and listing on the Hong Kong Stock Exchange
- Hygeia Healthcare Holdings Co., Limited in its US\$286 million IPO and listing on the Hong Kong Stock Exchange
- Yeahka Limited in its US\$212 million IPO and listing on the Hong Kong Stock Exchange
- Peijia Medical Limited in its US\$343 million IPO and listing on the Hong Kong Stock Exchange
- Akeso Biopharma in its US\$383 million IPO and listing on the Hong Kong Stock Exchange

Admissions

Bar Admissions

New York

Education

Northwestern University School of Law, J.D., 2003

New York University, Ph.D.,
Biochemistry, 2001

Peking University, B.S., 1994

- Guotai Junan Capital as sole sponsor and Guotai Junan Securities (Hong Kong) as main underwriter, and other underwriters in the US\$65 million IPO and listing of Zhongguancun Science-Tech Leasing on the Hong Kong Stock Exchange
- First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US\$71 Million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
- Shanghai Kindly Medical Instrument Co., Ltd., in its US\$106 million IPO and listing on the Hong Kong Stock Exchange
- Aesthetic Medical International Holdings in its US\$34.5 million IPO on the Nasdaq
- UP Fintech in its US\$120 million IPO on the NASDAQ
- Hua Medicine (2552.HK) in its US\$110 million Chapter 18A biotech company IPO sponsored by Goldman Sachs and CLSA Limited
- ShangPharma (NYSE: SHP) in its US\$87 million IPO and listing on the NYSE
- 3S Bio (NASDAQ: SSRX) in its IPO and listing on NASDAQ
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US\$133 million IPO of mobile game publisher FingerTango Inc.(6860.HK) on the Hong Kong Stock Exchange
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US\$40 million IPO of mobile game publisher Digital Hollywood Interactive Limited (2022.HK) on the Hong Kong Stock Exchange
- Viva Biotech (1873.HK) in its HK\$1,521.5 million (approximately US\$194 million) IPO and listing on the Hong Kong Stock Exchange
- Dexin China Holdings Company Limited (2019.HK) in its US\$190 million IPO and listing on the Hong Kong Stock Exchange
- Bank of Qingdao (03866.HK) in its US\$531 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Haohai Biological (6826.HK) in its US\$300 million IPO and listing on the Hong Kong Stock Exchange
- Credit Suisse and China Renaissance as joint bookrunners in the US\$53 million IPO and NYSE listing of ADS of Jupai Holdings Limited (NYSE: JP)
- eHi Car Services (NYSE: EHC) in its US\$120 million IPO and listing on the NYSE
- Phoenix Healthcare (01515.HK) in its US\$220 million IPO and listing on the Hong Kong Stock Exchange
- Credit Suisse and an American multinational banking and financial services holding company as joint bookrunners in the US\$110 million IPO and listing on the NYSE of Leju Holdings Ltd. (NYSE: LEJU)
- Credit Suisse and Goldman Sachs as joint bookrunners in US\$138 million IPO of Tarena Technologies Inc. (NASDAQ:TEDU) on the NASDAQ
- Morgan Stanley, Credit Suisse and Citigroup as lead underwriters on the US\$215 million US IPO of 58.com (NYSE: WUBA)
- Hengxing Gold (2303:HK) in its HK\$330.4 million (approximately US\$47 million) IPO and listing on the Hong Kong Stock Exchange

- Montage (NASDAQ: MONT) in its US\$70 million IPO and listing on NASDAQ
- China Polymetallic Mining Limited (2133.HK) in its US\$1.82 billion IPO and listing on the Hong Kong Stock Exchange
- a leading Chinese Internet television company in its US\$233 million IPO and listing on the NYSE
- a leading Chinese social network website in its US\$743 million IPO and listing on the NYSE
- one of the largest contract research organizations in China in its US\$87 million IPO and listing on the NYSE
- a provider of real estate information and consulting services in its US\$248 million IPO and listing on NASDAQ
- a leading Fujian-based property developer in its US\$210 million IPO and listing on the Hong Kong Stock Exchange
- the underwriters of a US\$212 million IPO and listing on the NYSE of a leading contract research organization in China
- a major Chinese bank in its US\$5.4 billion IPO and listing on Hong Kong Stock Exchange and Shanghai Stock Exchange
- a major Chinese bank in its US\$9.2 billion IPO and listing on Hong Kong Stock Exchange and Shanghai Stock Exchange
- a biopharmaceutical company in its IPO and listing on NASDAQ
- the underwriters in the IPO of a New York-based real estate investment company
- a real estate finance group in its IPO and subsequent debt offering
- the underwriters in the 144A/Regulation S offering of a New York-based specialty finance company that invests in real estate-related securities and other asset classes

M&A and Cross-border Corporate Finance

- Ansun Biopharma, Inc. in its US\$80 million Series B financing
- Distinct Healthcare in its US\$60 million Series D financing
- TTM technologies (NASDAQ: TTMI), a leading global printed circuit board (PCB) manufacturer, on the US\$660 million divestiture of its four China manufacturing plants comprising substantially all of the assets of its Mobility business, to AKMMeadville Electronics (Xiamen) Co., Ltd.
- Consortium led by controlling shareholders of SORL in the going private transaction of SORL Auto Parts (NASDAQ: SORL)
- Essence International in Highpower's going-private transaction
- the Meinian buyer consortium in a competing going private bid against management for Chinese healthcare Company iKang Healthcare Group (NASDAQ: KANG)
- the buyer consortium in the going private transaction of Zhaopin (NYSE: ZPIN)
- Chinese hotel chain Homeinns (NASDAQ: HMIN) in US\$1.75 billion going private transaction
- Goldstone Investment as a member of buyer consortium in the going private transaction of Bona Film (NASDAQ: BONA)
- Julius Baer in its US\$18 million PIPE investment in Jupai (NYSE: JP), a Chinese wealth management company

- Anshan Hecheng in subscribing for a majority of shares in a Nasdaq-listed Chinese battery manufacturer, Highpower's PRC subsidiaries (NASDAQ: HPJ)
- Pudong Science and Technology Investment (PDSTI) in its US\$100 million investment in Icon Aircraft, Inc.
- Jiangsu Phoenix Education Publishing Co., Ltd. in its US\$80 million acquisition of the assets relating to the children's book business of Publication International Ltd. (PIL) and PIL's subsidiaries
- PDSTI in its acquisition of 14.9% of outstanding shares of common stock of LightPath (NASDAQ: LPTH), a US optical instrument manufacturer
- special committee of ShangPharma (NYSE: SHP) in evaluating going private bid from TPG and company's chairman
- special committee of Feihe (NYSE: ADY) in evaluating going private bid from MSPEA and company's chairman
- China Real Estate Information Corporation (NASDAQ: CRIC) in evaluating going private bid
- two private equity firms leading a consortium in a US\$600 million pre-IPO investment
- a large private equity firm in its investment in a Chinese bank as part of a consortium led by a European bank
- a major automaker in a US\$62 billion sale
- a Chinese bank in a strategic investment
- a China-based energy and chemical company in its zero coupon convertible bond offering
- a US bank in its sale of a secured loan portfolio

Professional Activities

Publications

- "Accessing Capital Through Customised PIPE Offerings," *Eurekahedge e-newsletter* (November 15, 2016)
- "Should China Provide Intellectual Property Protection for Genetically Modified Animals?" *Northwestern Journal of International Law and Business* (Winter 2003)

Honors & Awards

- Recognized by *IFLR1000* as a "Notable Practitioner" in the practice area of Mergers & Acquisitions (China) (2019 & 2020)

Languages

- Mandarin Chinese